Dopaminergic cell transplantation is a promising therapeutic approach for the treatment of Parkinson's disease, the potential of which is limited due to poor survival and low dopamine content within engrafted tissue. In this study, the ability of transforming growth factor-β2 (TGF-β2) to influence transplant survival was evaluated. Cell suspensions containing fetal rat ventral mesencephalon (VM) cells were incubated prior to surgery with vehicle (DPBS), varying concentrations of TGF-β2 (5-1000 ng/ml), or a pan-specific antibody against TGF-β (1D11, 100 ng/ml). VM cell suspensions (200,000 cells) were unilaterally implanted into the striatum of adult Sprague-Dawley rats (n = 5-11 animals/group). Following a 3-week survival period, small but viable VM grafts containing tyrosine hydroxylase-positive (TH+) neurons and fibers were present in all animals. Addition of TGF-β2 resulted in a steep, bell-shaped dose-response curve with a significant effect on TH+/dopamine cell survival. At 50 ng/ml TGF-β2, the number of surviving dopamine neurons was increased twofold compared with controls. Addition of TGF-β2 or 1D11 did not significantly influence graft volume. Further studies, possibly in combination with other neurotrophic factors, need to be performed to obtain a greater understanding of the effects of TGF-β on dopamine neurons and fetal VM cell engraftment.
INTRODUCTION
tissue (2, 13, 18, 19, 36, 37, 40, 44, 51, 54) ; altering the physical properties of the graft or host (e.g., lowering the Transplantation of dopamine (DA)-containing fetal body temperature of the graft recipient) (22); or optimizventral mesencephalon (VM) cells into the striatum is a ing the surgical procedure as in the micrografting appromising treatment for Parkinson's disease (5,11,15,20, proach described by Nikkhah et al. (39) . In particular, 34, 47) . Numerous preclinical and clinical studies demthe addition of trophic agents prior to, during, or after onstrated survival and engraftment of dopamine neurons implant variably increased graft volume and/or doparesulting in a significant improvement in parkinsonian mine cell survival (9) . symptoms (4, 5, 16, 20, 32) . However, the potential of this Transforming growth factor-β (TGF-β) is part of a therapy is limited, in part, due to the poor survival and large family of cytokines with pleiotropic effects on anilow content of dopamine neurons within the implant. mal and cell physiology, including wound healing, ex-General estimates of cell survival are on the order of tracellular matrix regulation, modulation of inflamma-10% (7) (8) (9) 17, 39) , and careful dissection of the fetal VM tory cell infiltration, and immune modulation (33) . TGFyields less than 5% dopamine neuron content within β exists as three isoforms in mammals (TGF-β1, 2, and the cell suspension or tissue fragment used for implanta-3) with varying and often complex effects on neural tistion (10) .
sues (14, 24, 42, 52) . In the central nervous system (CNS), A variety of methods have been evaluated aimed at TGF-β is a potent neurotrophic factor with direct influincreasing graft survival and dopamine content. These ences on cell growth, development, and differentiation. include the addition of biologically active agents (such In vitro, TGF-β2 regulates the survival of DA neurons as cytoprotectants and neurotrophic factors) to transplant (26, 41) , and protects against toxin-induced degeneration 246 MACAULEY ET AL.
(23,25). Although there is considerable evidence that to approximately 95%. Anti-TGF-β antibody, 1D11, was produced at Genzyme as a monoclonal IgG1 antibody in TGF-β exerts powerful neurotrophic and neuroprotective effects on DA neurons in culture, the effect of SP2/0 myeloma cells and purified on a protein G column to 95% as assessed by SDS-PAGE. TGF-β on DA survival in vivo has not been investigated to date.
Based on these neurotrophic and neuroprotective prop-Transplantation erties, this study investigated whether TGF-β2 could en-Animals were anesthetized with ketamine/xylazine hance dopaminergic graft survival. VM cell suspensions (±diazepam) and the head mounted in a stereotaxic were preincubated with TGF-β2 across a wide range of frame. Two deposits (1 µl each) of VM cell suspension concentrations (5-1000 ng/ml), vehicle control, or 1D11, were injected into the right striatum (coordinates: A/P: a pan-specific antibody to TGF-β, and then implanted +1.0, M/L: −2.5, D/V: −4.5 and −5.5 mm, from bregma) into the nonlesioned rat striatum. Following a 3-week at a rate of 0.2 µl/min through a 26-gauge needle survival, the influence of pretreatments on graft volume attached to a Hamilton syringe (200,000 total cell dose). and dopamine content was investigated.
The needle was left in place for 10 min after the second injection, then slowly withdrawn. Animals (n = 5-11/ MATERIALS AND METHODS group) were assigned to one of eight groups based on Experimental Animals pretreatment of cells with TGF-β2, 1D11, or vehicle (sa-Adult male and female Sprague-Dawley rats (Taline) as described above. Animals were transplanted conic, Germantown, NY) were housed under 12:12-h over the course of several different surgical days. A light/dark cycle and provided food and water ad libitum. combination of experimental doses and vehicle treat-All procedures were carried out under an approved ments was used on each day to counterbalance any bias IACUC protocol and in accordance with guidelines for on graft results for a given surgical session. the use of animals in research (38).
Histology Preparation of Fetal Ventral Mescencephalic Cell Suspension
At 20 days postimplantation, animals were deeply anesthetized and transcardially perfused with phosphate-The floor of the VM was isolated from E14 rat embuffered 2% paraformaldehyde/0.03% glutaraldehyde. bryos (day of mating counted as day 0). The VMs were
The brains were removed and postfixed for 48 h. Serial dissected in Ca 2+ -and Mg 2+ -free Dulbecco's phosphate coronal sections were cut on a vibratome or cryostat at buffered saline (DPBS) and incubated in 0.05% trypsina 50-µm thickness. Brains cut with a cryostat were pro-EDTA for 10 min. The VM tissue was then washed in tected in sucrose prior to freezing. Two series of free-Hanks buffered salt solution (HBSS) containing 50 µg/ floating sections (spaced 300 µm apart), spanning the ml human recombinant DNase and dissociated by using rostro-caudal extent of the striatum, were set aside for a three-step trituration process. Tissue was passed through staining. The first series was washed in 0.1 M potassium three precalibrated Pasteur pipettes with decreasingly phosphate buffer saline (kPBS) and preincubated in 5% smaller apertures (Ϸ1, 0.7, and 0.5 mm), resulting in a normal goat serum (NGS) and 0.25% Triton X-100 in single cell suspension. VM cell suspensions were centri-kPBS for 3 h. Sections were then incubated overnight in fuged at 1000 rpm for 5 min at room temperature (RT), kPB containing a polyclonal antibody to tyrosine hyresuspended in sterile Ca 2+ -and Mg 2+ -free DPBS, and droxylase (TH, 1:4000; Pel-Freez), 5% NGS, and 0.2% stored overnight at 4°C prior to transplant. Cell viability Triton X-100 at 4°C. The sections were rinsed in kPB was checked the next morning and averaged 93% using and incubated for 1 h in a biotinylated goat anti-rabbit trypan blue dye. One to four hours prior to surgery, IgG (1:200 diluted in 0.1% BSA, 0.1% Triton X-100 in TGF-β2 (5, 10, 50, 100, 500, or 1000 ng/ml), 1D11 (100 kPBS; Vector Labs). The tissue was rinsed in kPB and ng/ml, a pan-specific antibody to TGF-β), or vehicle incubated in peroxidase-conjugated avidin-biotin comalone (DPBS) was added to the cell suspension, and fiplex (1:50 diluted in 0.1% BSA, 0.1% Triton X-100 in nal cell density was adjusted to 100,000 viable cells/µl kPBS; Vector Labs) for 1 h at room temperature. Antiusing DPBS. The VM cell suspensions, containing the body binding was visualized by reaction of the sections varying concentrations of TGF-β, vehicle, or 1D11 were with 3′,3′-diaminobenzidine and hydrogen peroxide. then used for transplantation.
Stained sections were mounted on gel-coated slides, de-Test Materials hydrated, and coverslipped. The second series of sections through each graft was mounted on gel-coated Recombinant human TGF-β2 (100 mg/ml) was produced at Genzyme in Chinese hamster ovary cells and slides, stained for hematoxylin and eosin (H&E), dehydrated, and coverslipped. purified on cation exchange and reversed phase columns
Quantitative Graft Histology
rons was significantly different, F(7, 44) = 3.0849, p < 0.0098. Pretreatment with TGF-β2 yielded a steep, bell-Slides were read under blinded conditions for all shaped dose-response curve in relation to graft TH+ cell quantitative analysis. The number of TH+ neurons prescontent, with a maximal effect at 50 ng/ml ( Fig. 3 ). ent within the entire boundaries of the graft (including Compared with the saline control, the number of TH+ cells that effluxed into the corpus callosum and cortex) cells in the 50 ng/ml TGF-β2 group was increased for each section was counted at 20× magnification under roughly twofold (203 ± 32 vs. 390 ± 105, p < 0.0048). brightfield microscopy and recorded. The total number
The number of TH+ graft neurons in the 10 ng/ml TGFof TH+ cells/graft was estimated by multiplying cell β2 group was increased (nonsignificantly) by 20% over counts by 6; every sixth section was stained and counted saline control. All other TGF-β2 treatment groups had through the graft. Counts were corrected using Abermean TH+ cell counts that fell below control values, but crombie's formula (1) (cell diameter = 40 µm, section none of these group comparisons reached significance. thickness = 50 µm). Graft area was measured in TH+ There was no effect of pretreatment of cells with antistained tissue sections as margins were easily distin-TGF-β antibody, 1D11, on TH+ cell counts. Across all guished between transplanted cells and displaced host engrafted animals, there was a significant, positive cortissue. The graft outline was traced from digital images relation between the number of TH+ cells and graft volacquired using a SPOT camera interfaced with a comume (r = 0.547, p < 0.05) independent of treatment group. puter. Area (mm 2 ) was determined using the SCION Im-However, TH cell density (TH count/graft volume) was age program (ported from NIH Image for the Macintosh significantly (p < 0.0002) increased in the 50 ng/ml by Scion Corporation and available on the Internet at group, consistent with a selective effect of TGF-β2 on http://www.scioncorp.com). Graft volume (mm 3 ) was then dopamine survival postimplant. estimated as the sum of the graft areas multiplied by the distance between sections. The results for TH+ cell DISCUSSION counts and graft volume were calculated as means ± Neural transplantation, as a form of dopamine cell SEM. Each set of data was subjected to one-way analyreplacement therapy for Parkinson's disease, has yielded sis of variance (ANOVA) and a Fischer LSD post hoc encouraging results in preclinical models as well as in a test.
limited series of human cases (5, 11, 15, 20, 34, 47) . However, these early gains have been tempered by a growing RESULTS perception that clinically meaningful engraftment on a General Graft Histology large scale awaits significant improvements in transplan-Small, but viable, grafts were present in all 52 imtation technology. The two most notable technical shortplanted animals. Grafts typically were compact, rounded comings are relatively poor cell survival and low dopaor elongate clusters of cells that displaced host striatal mine cell content. In response, a large effort has been tissue ( Fig. 1A) . Grafted cells were often found extendgenerated in preclinical models investigating methods to ing dorsally along the injection tract with a small secimprove suboptimal engraftment including trophic supondary deposit in the corpus callosum and deeper layers plementation of grafted tissues and cells. of the overlying cortex. By H&E staining, grafts were Within this context, the present study evaluated graft populated by large, rounded cells that were well inteaugmentation through the addition of TGF-β2 to the VM grated, having indistinct margins with the host brain cell suspension prior to transplant. TGF-β was not eval-( Fig. 1B) . Scattered macrophages were present along the uated previously in this model despite considerable eviinjection tract in some animals, but there was no evidence that it has potent developmental, neurotrophic, dence of vascular cuffing or small cell infiltration sugand neuroprotective effects on midbrain dopamine neugestive of graft rejection. Graft size was fairly uniform rons. Across a wide range of concentrations (5-1000 ng/ across experimental groups (Fig. 2) with an average volml), TGF-β2 yielded a maximal survival effect at 50 ng/ ume of 0.679 ± 0.130 mm 3 (±SEM). There was no sigml with roughly a twofold increase in cell numbers over nificant effect of TGF-β2 pretreatment on graft volume, vehicle-treated animals. This magnitude of effect is F(7, 44) = 0.689, p ≤ 0.6805. comparable to numerous other factors previously used to supplement grafted tissue (9) . However, grafts in the TH Cell Survival present study were small with relatively low numbers of surviving TH+ cells. The effects of TGF-β2 on dopa-Densely stained TH+ cells and fibers were present to varying degrees within all grafts. TH+ cells were typi-minergic survival should be interpreted with caution pending further study of the molecule on larger grafts, cally dispersed along the outer margins with TH+ fibers and isolated cell bodies extending through the interior possibly in combination with 6-OHDA denervation of the host striatum (see below). Nevertheless, the effective (Fig. 1C, D) . Across all groups, the number of TH+ neu- concentration range of 10-50 ng/ml on TH survival in quent engraftment. The concentration of 1D11 used in this study (100 ng/ml) is known to completely inhibit vivo for TGF-β2 compares favorably with its in vitro activity. We found that concentrations of TGF-β2 as low TGF-β activity using in vitro assays (48) . To date, multiple transplant approaches have been as 20 ng/ml significantly increased the survival of dopamine neurons within VM cultures (personal observa-used, making it difficult to compare the efficacy of graft supplements on TH cell survival. This study used a typi-tion). Other investigators have also reported that TGF-β2 in this concentration range increased dopamine cell cal cell "dose" of 200,000 cells/implant, and implantation was made into normal striatum as opposed to survival in vitro (23, 25, 26, 41) .
At concentrations of TGF-β2 greater than 50 ng/ml, striatum denervated of dopaminergic innervation by 6hydroxydopamine. It remains unclear if the denervated the beneficial effects on TH cell survival in VM grafts were lost, suggesting that there may be an optimal con-striatum is a more appropriate environment in which to evaluate graft survival (46, 49) . Lesion-induced changes centration of TGF-β/receptor occupancy required for efficacy. This kind of dose-response curve is also seen in endogenous trophic expression within host striatum could influence the effect of TGF-β on subsequent TH in other aspects of TGF-β biology. For example, neutrophil and eosinophil chemotaxis show a similar bell-cell survival within the VM grafts. While the action of TGF-β on nervous tissue is often shaped response (35, 43) . The results highlight that cell survival in response to a "simple" additive may be quite characterized as neurotrophic-like, it is clear that it has a more complex biological relationship with the nervous complex (more may not be better) and underscores the need to do rigorous dose-response testing. Though no system (31) . In particular, several studies by Krieglstein et al. (24, 27, 29) demonstrated that the main activity of benefit was demonstrated, extremely high concentrations of TGF-β2 (up to 1000 ng/ml) did not have a dele-TGF-β may be to regulate the relative potency of other neurotrophic factors. In vitro, the addition of TGF-β2 terious effect on graft survival or host brain. Likewise, addition of a pan-specific antibody to TGF-β (1D11) to (as well as TGF-β3) synergistically increased trophic activity of CNTF, GDNF, and FGF-2 (28-30,53). In some the VM cell suspension had no apparent effect on subse- cases (e.g., chick ciliary ganglion cultures), TGF-β was transplant when tissues were incubated in growth factors for 2 h before transplant. In the present study, following found to have no survival-promoting effects unless it was co-incubated with another trophic factor (28).
3-week survival, dopaminergic morphology had taken on a fairly mature appearance with elaboration of pro-Subsequent transplant experiments should investigate whether incubating cells with cocktails of TGF-β2 and cesses and the presence of large TH+ cells along the periphery of the VM graft or clustered within the inte-GDNF or other factors will act synergistically to increase cell survival and engraftment.
rior. This length of survival is well past the critical period of cell death, and similar studies on trophic supple-The window of opportunity for manipulating grafts extends from initial dissection of donor tissue to chronic mentation have used time points in the range of 2-8 weeks. treatment of the host following implantation. Previous studies found that the majority of cell death occurs dur-An exciting new advancement in transplant technology is the use of stem cells, particularly neural stem ing mechanical dissociation of VM tissue or within the first few days following transplant (3, 6, 12, 21, 49, 50, 55) .
cells (45) . The ability to culture and expand a cell source for transplantation offers significant advantages over the In this study, TGF-β2 was added to the cell suspension a few hours prior to transplant. This was considered a use of freshly derived tissue. Culturing of cells allows for in vitro manipulation, and already a tremendous ef-simple, practical, clinically relevant way to provide trophic supplementation immediately prior to and during fort has been directed at ways to induce and enrich for dopaminergic phenotype in neural stem cells. Here, too, the initial engraftment period, which is a critical period of cell death for dopamine neurons. An earlier study by the multiple activities of TGF-β, as a developmental factor, a trophic regulator, and possibly a differentiating Zawada et al. (55) demonstrated increased numbers of TH+ cells and reduced apoptotic profiles at 24 h post-agent, should be carefully assessed.
